Saturday, March 27, 2021

Doripenem in VAP

 Q: Doripenem is highly effective among all carbapenems in ventilator-associated pneumonia (VAP)? 

A) Yes 

B) No

Answer: B

Doripenem became popular for VAP as they were found to be more potent in vitro against P. aeruginosa. But subsequent follow-up study showed increased 28-days mortality in VAP patients. In fact, the study was stopped early. This leads FDA to add a warning on Doripenem for use in VAP patients.



1. Kollef MH, Chastre J, Clavel M, et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care 2012; 16:R218. 

 2. US Food and Drug Administration. FDA approves label changes for antibacterial Doribax (doripenem) describing increased risk of death for ventilator patients with pneumonia. (Last accessed on March 11, 2021).

3. Paterson DL, Depestel DD. Doripenem. Clin Infect Dis 2009; 49:291.

No comments:

Post a Comment